Ten stocks fell sharply on Wednesday, bucking a broader market optimism, as investor sentiment was dented by mostly weak earnings performance and outlook, among other factors. Of the 10 firms, two fell to their lowest 52-week prices.
Meanwhile, all Wall Street major indices finished in the green, led by the Nasdaq with a 0.65 percent gain, followed by the Dow Jones, up 0.48 percent, and the S&P 500 with 0.37 percent.
In this article, we name the 10 worst-performing companies on Wednesday and break down the reasons behind their drop.
To come up with the list, we considered only the stocks with a $2 billion market capitalization and more than 5 million shares in trading volume.
Stock market data on a laptop screen. Photo by Alesia Kozik on Pexels
10. SSR Mining Inc. (NASDAQ:SSRM)
SSR Mining fell by 10.23 percent on Wednesday to close at $19.48 apiece as investor sentiment was dampened by a weak production outlook for full-year 2025, despite reporting a stellar earnings performance in the third quarter.
In its financial statement, SSR Mining Inc. (NASDAQ:SSRM) said it expects full-year production to settle in the lower range of its previous 410,000 to 480,000 gold equivalent ounce guidance range.
Additionally, consolidated costs were projected to hit the upper end of its guidance range as a result of higher-than-expected gold prices on royalty costs alongside its strong share price performance on share-based compensation.
In the third quarter of the year, SSR Mining Inc. (NASDAQ:SSRM) said net income attributable to shareholders surged by 523 percent to $65.4 million from $10.5 million in the same period last year. Revenues increased by 50 percent to $385.8 million from $257.3 million year-on-year.
“Our third quarter operating results were generally aligned to our internal plans, and we continue to expect that a solid fourth quarter will bring us within consolidated 2025 production guidance,” said SSR Mining Inc. (NASDAQ:SSRM) Executive Chairman Rodney Antal.
“We have numerous growth opportunities across the portfolio, particularly in Türkiye where we continue to advance requirements towards a restart of operations at Çöpler. Together with the Hod Maden investment decision, we look forward to showcasing the significant potential upside ahead for our shareholders,” he noted.
9. Live Nation Entertainment, Inc. (NYSE:LYV)
Live Nation snapped a three-day winning streak on Wednesday, shedding 10.59 percent to close at $134.79 apiece after posting a weak profit in the third quarter of the year.
In an updated report, Live Nation Entertainment, Inc. (NYSE:LYV) said net income attributable to shareholders dropped by 4.6 percent to $431 million from $451.8 million in the same quarter last year, dragged by higher expenses during the period.
Revenues, on the other hand, increased by 11 percent to $8.5 billion from $7.65 billion year-on-year.
Looking ahead, Live Nation Entertainment, Inc. (NYSE:LYV) remained upbeat about its outlook for next year, saying that it is “off to a strong start with a double-digit increase” from large-venue shows.
“At the same time, we’re continuing to invest in new venues to grow the market, create jobs, and give artists even more ways to reach fans, positioning Live Nation on a clear path for double-digit operating income and AOI growth this year and compounding at this growth level over the next several years,” said Live Nation Entertainment, Inc. (NYSE:LYV) President and CEO Michael Rapino said.
8. Super Micro Computer, Inc. (NASDAQ:SMCI)
Super Micro extended its losing streak to a third straight day on Wednesday, shedding 11.52 percent to close at $42.03 apiece after announcing disappointing earnings results in the first quarter of fiscal year 2026.
In an updated report, Super Micro Computer, Inc. (SMCI) said its net income fell by 60 percent to $168.28 million from $424 million in the same period last year, as net sales declined by 15 percent to $5 billion from $5.9 billion year-on-year.
For full-year 2026, Super Micro Computer, Inc. (NASDAQ:SMCI) expects net sales to grow by 64 percent to $36 billion from the $21.97 billion in the full fiscal year of 2025.
In the second quarter alone, net sales are targeted at $10 billion to $11 billion, with GAAP diluted earnings per share of $0.37 to $0.45.
“Powered by DCBBS (Data Center Building Block Solutions), Supermicro is expanding/transforming into a leading AI and datacenter infrastructure company, delivering total solutions that simplify deployment, accelerate time-to-market, and reduce TCO (total cost of ownership),” said Super Micro Computer, Inc. (NASDAQ:SMCI) President and CEO Charles Liang.
7. Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS)
Kratos saw its share prices decline by 14.20 percent on Wednesday to close at $77.41 apiece as investors turned cautious about its full acquisition of Israel-based Orbit Technologies for $356.3 million.
In a statement, Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) said it signed a definitive agreement with Orbit for the acquisition of a 100-percent stake, which will be fully funded through cash.
Orbit is a global provider of mission-critical satellite-based communication systems for mobile and unmanned aerial, seaborne, undersea, and land systems, military vehicles, and other systems that services to major air forces, traditional prime contractors, and emerging new defense and space companies.
“Orbit checks every box in a Kratos acquisition, including outstanding leadership and culture, mission-committed employees and leading technology, with real, battle-proven hardware, products and systems that are in Kratos’ sweet spot. Additionally, major customers of Orbit are also existing customers of Kratos, including in Israel, the United States, Europe, India and elsewhere, adding to our conviction in this transaction’s projected success for all parties involved, including Kratos shareholders,” said Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) President and CEO Eric DeMarco.
Meanwhile, Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) also announced a strong earnings performance in the third quarter of the year, with net income jumping 172 percent to $8.7 million from $3.2 million in the same period last year.
Revenues increased by 26 percent to $347.6 million from $275.9 million year-on-year.
6. Hinge Health, Inc. (NYSE:HNGE)
Hinge Health ended a three-day winning streak on Wednesday, slashing 15.06 percent to finish at $45.39 apiece as investor sentiment was dampened by a disappointing earnings performance, having swung to a net loss in the third quarter of the year.
In its financial statement, Hinge Health, Inc. (NYSE:HNGE) said it fell to a net loss attributable to shareholders of $1.8 million from a $72,000 net income in the same period last year, amid higher operating expenses and loss from operations.
Operating loss stood at $6.1 million, or a 56.4 percent jump from the $3.9 million in the same comparable period.
Revenues, on the other hand, jumped by 53 percent to $154.2 million from $100.6 million.
Looking ahead, Hinge Health, Inc. (NYSE:HNGE) remained upbeat about its outlook for the fourth quarter and full-year 2025.
For 2025, the company expects revenues to hit $572 million to $574 million, or a 47 percent year-on-year growth at the midpoint.
For the fourth quarter, revenues are expected to grow by 33 percent year-on-year to a range of $155 million to $157 million.
5. Zimmer Biomet Holdings, Inc. (NYSE:ZBH)
Zimmer dropped its share prices by 15.15 percent on Wednesday to end at $87.55 apiece as investors soured on its organic sales growth forecast amid weakness in international markets, alongside a weak earnings performance in the third quarter of the year.
During its earnings call, Zimmer Biomet Holdings, Inc. (NYSE:ZBH) maintained its overall revenue growth forecast but lowered the organic growth outlook to 4 percent to 4.5 percent, amid last-minute order cancellations.
“Our strong performance in the US was partially offset by weakness in Latin America, Emerging Markets in Europe and non-core businesses, which emerged late in the quarter and are being addressed,” CEO Ivan Tornos said.
In the third quarter of the year, Zimmer Biomet Holdings, Inc. (NYSE:ZBH) saw its net income drop by 7.3 percent to $230.9 million from $249.1 million in the same period last year. Net sales grew by 9.7 percent to $2 billion from $1.8 billion year-on-year.
“Our third quarter performance was anchored by 5.6 percent organic revenue growth in our critical US business, driven by accelerated adoption of our key new products referred to as the ‘Magnificent Seven,’” Tornos said.
”This is highly encouraging, especially as we prepare to launch a second round of new-to-the-world technologies, including the first fully autonomous robot in orthopedics and our iodine-treated hip, the world’s first orthopedic implant with Iodine Technology that inhibits bacterial adhesion and prevents biofilm formation to help address Periprosthetic Joint Infections. We are excited to launch our iodine-treated hip in Japan soon, having received PMDA approval in September,” he added.
4. Pinterest Inc. (NYSE:PINS)
Pinterest dropped for a second day on Wednesday, slashing 21.76 percent to close at $25.75 apiece—just $1.62 shy of its 52-week low—after missing analysts’ earnings estimates.
In its third quarter report, Pinterest Inc. (NYSE:PINS) posted earnings per share of $0.38, missing analyst expectations of $0.42.
However, Pinterest Inc. (NYSE:PINS) reported stellar earnings during the period, with net income expanding by 201 percent to $92.1 million from $30.5 million in the same period last year.
Revenues were also higher by 17 percent at $1.049 billion versus $898 million year-on-year.
“Our investments in AI and product innovation are paying off. We’ve become a leader in visual search and have effectively turned our platform into an AI-powered shopping assistant for 600 million consumers. In turn, global advertisers are increasingly counting on Pinterest as a go-to search platform to reach their customers and drive sales,” said Pinterest Inc. (NYSE:PINS) CEO Bill Ready.
For the fourth quarter of the year, Pinterest Inc. (NYSE:PINS) expects revenues to be in the range of $1.313 billion to $1.338 billion, representing a 14 to 16 percent growth year-on-year.
“Our guidance assumes the impact of foreign exchange to be approximately 1 point of tailwind, based on current spot rates. We expect Q4 2025 Adjusted EBITDA to be in the range of $533 million to $558 million,” the company added.
3. Perrigo Company plc (NYSE:PRGO)
Perrigo fell to a new 52-week low on Wednesday, extending to a three-day losing streak, as investor sentiment was dampened by weak net sales and news that it was conducting a strategic review of its infant formula business.
At intra-day trading, the stock dropped to its lowest level of $15.05 before gaining 5 cents back to end the day just down by 25.21 percent at $15.10 apiece.
In an updated report, Perrigo Company plc (NYSE:PRGO) said that net sales dipped by 4 percent to $1.043 billion from $1.087 billion in the same period last year, dragged by lower organic sales and the impact of its divestitures and exited products.
Despite the results, Perrigo Company plc (NYSE:PRGO) swung to a net income of $7.5 million, reversing a $21 million net loss in the same period last year.
In other news, Perrigo Company plc (NYSE:PRGO) said that it was conducting a strategic review of its infant formula business, which could open the door for a sale.
“This proactive review is about discipline and ensuring the company’s portfolio is best positioned for sustainable growth and free cash flow generation,” said Perrigo Company plc (NYSE:PRGO) President and CEO Patrick Lockwood-Taylor.
“While our infant formula operations have stabilized, the external environment has quickly changed, making a fit with our consumer health OTC businesses less strategic. Whatever path we choose, our corporate priorities are clear: reduce leverage, sustain our dividend policy, continue to deliver on customer partnerships and sharpen focus on our high-potential OTC portfolio to reach more consumers and drive household penetration,” he added.
2. Soleno Therapeutics Inc. (NASDAQ:SLNO)
Soleno Therapeutics extended its losing streak to a 5th consecutive day on Wednesday, slashing 26.59 percent to close at $46.87 apiece as investors appeared to have priced in a strong earnings performance in the third quarter of the year.
The maker of the first and only FDA-approved drug for hyperphagia said in an updated report that it swung to a net income of $26 million, or a 134 percent improvement from the $76.6 million net loss in the same period last year. It also incurred revenues of $66 million during the quarter.
“Our strong third quarter results reflect growing awareness of the compelling efficacy and safety profile of Vykat XR within the PWS community,” said Soleno Therapeutics Inc. (NASDAQ:SLNO) Chairman and CEO Anish Bhatnagar.
“As the first and only FDA-approved therapy to treat the hallmark symptom of PWS—hyperphagia—in patients 4 years and older, Vykat XR can offer a new option to this fragile and complex patient population that often suffers from a multitude of serious co-morbidities … and we are working tirelessly to make it as broadly accessible as possible,” he added.
1. Trex Company, Inc. (NYSE:TREX)
Trex Company dropped to a new 52-week low on Wednesday after three consecutive days of declines, as investors sold off positions after the company withdrew its growth guidance for full-year 2025, now expecting figures to end flat year-on-year.
At intra-day trading, Trex Company, Inc. (NYSE:TREX) fell to its lowest price of $32.14 before paring losses to end the day just down by 31.06 percent at $32.43 apiece.
“Our year-to-date sales growth of 3 percent was led by railing sales, which are tracking to double-digit growth for the full year. We now expect, however, that several factors will cause our fourth quarter sales to be below our original expectations,” Trex Company, Inc. (NYSE:TREX) said.
“First, we are seeing continuing weakness in the Repair and Remodel sector in what also is the seasonally slowest quarter of the year. In addition, we expect that our distribution partners will manage their end-of-year inventories to lower levels through the end of the year. Thus, we currently expect fourth quarter sales to range from $140 million to $150 million, bringing full-year 2025 sales guidance to $1.15 billion to $1.16 billion, approximately flat with our reported sales in 2024,” it noted.
The company also revised its full-year adjusted EBITDA margin guidance to range from 28.0 percent to 28.5 percent.
Following the announcement, shareholder law firm Hagens Berman said that it initiated an investigation to look into whether Trex Company, Inc. (NYSE:TREX) misled investors about adverse trends impacting its business.
In the third quarter of the year, the listed firm saw net income jump by 28 percent to $51.77 million from $40.55 million in the same period last year. Revenues increased by 21.9 percent to $285 million from $233.7 million year-on-year.
While we acknowledge the potential of TREX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TREX and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.
